

A phase II trial of docetaxel, cisplatin and 5-fluorouracil (5-FU) chemotherapy in locally advanced and metastatic carcinoma of the penis

Submission date 30/01/2008	Recruitment status No longer recruiting	☒ Prospectively registered ☐ Protocol
Registration date 30/04/2008	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 26/10/2018	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol

<http://cancerhelp.cancerresearchuk.org/trials/trial-chemotherapy-cancer-penis-penile-tpf>

Contact information

Type(s)

Scientific

Contact name

Dr Amit Bahl

Contact details

Bristol Haematology & Oncology Centre
Horfield Road
Bristol
United Kingdom
BS28ED

Additional identifiers

Protocol serial number

ICR-CTSU/2008/10016

Study information

Scientific Title

A phase II trial of docetaxel, cisplatin and 5-fluorouracil (5-FU) chemotherapy in locally advanced and metastatic carcinoma of the penis

Acronym

Penile TPF

Study objectives

The goal is to determine, in inoperable cancer of the penis, the feasibility and efficacy of giving chemotherapy consisting of two drugs that are known to be active (cisplatin and 5-fluorouracil [5-FU]) with a newer drug, docetaxel. This combination (TPF) has been proven to be highly active in some similar cancers. This is a limited phase II trial to gain insight into the potential activity of this regimen.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Non-randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Penis cancer

Interventions

All participants will receive the same regimen. The regimen consists of docetaxel 75 mg/m² day 1 + cisplatin 60 mg/m² day 1 + 5FU 750 mg/m² days 1-5 with a cycle of 21 days, three cycles to be given in total prior to formal re-staging.

Intervention Type

Drug

Phase

Phase I/II

Drug/device/biological/vaccine name(s)

Cisplatin, 5-Fluorouracil, docetaxel

Primary outcome(s)

Overall response rate (complete remission rate + partial remission rate). This will be objectively assessed by magnetic resonance imaging (MRI) or computed tomography (CT) scan after completion of the proposed 3 cycles of TPF chemotherapy or at the time of discontinuation of chemotherapy. Scans will be reviewed centrally to confirm outcome.

Key secondary outcome(s)

1. Proportion of patients with inoperable locoregional disease rendered operable by TPF chemotherapy. Timepoints of measurement not yet defined as of 30 January 2008
2. Progression-free survival. Timepoints of measurement not yet defined as of 30 January 2008.
3. Overall survival. Duration of follow-up not yet defined as of 30 January 2008.
4. Acute toxicity (as determined by Common Toxicity Criteria [CTC]) after each cycle and at 3 months
5. Late toxicity (CTC). Timepoints of measurement not yet defined as of 30 January 2008.

Completion date

01/06/2010

Eligibility

Key inclusion criteria

Patients with cancer of the penis fit to receive chemotherapy as palliative or definitive treatment or as treatment on relapse will be eligible. It is expected that the decision to include some groups of patients (e.g., Stage T3, N1 patients) will depend on local policy - discussion within the multidisciplinary Team (MDT) of all eligible patients will be encouraged.

Inclusion criteria:

1. Male, >18 years
2. Histologically-proven squamous cell carcinoma of the penis
3. Eligible disease stage:
 - 3.1. M1
 - 3.2. M0, Tx, N3 (i.e. involvement of deep inguinal or pelvic lymph nodes)
 - 3.3. M0, Tx, N2 (i.e. involvement of multiple or bilateral superficial lymph nodes) and deemed inoperable by MDT
 - 3.4. M0, T3 N1 (tumour invades urethra or prostate and single inguinal lymph node involved)
 - 3.5. M0, T4 (tumour invades other adjacent structures) (any N)
4. Glomerular filtration rate (GFR) greater or equal to 60 ml/min
5. Written, informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

Male

Key exclusion criteria

1. Pure verrucous carcinoma of the penis
2. Squamous carcinoma of the urethra
3. T1 N1 M0 disease
4. T2 N1 M0 disease
5. T3 N1 M0 where the MDT feels that neoadjuvant chemotherapy is not advisable
6. Unfit for this regimen (as assessed by the MDT)
7. Previous chemotherapy
8. Previous radiotherapy (subsequent radiotherapy for loco-regional consolidation is permitted)
9. Contraindication to chemotherapy

Date of first enrolment

01/06/2008

Date of final enrolment

01/06/2010

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Bristol Haematology & Oncology Centre

Avon

United Kingdom

BS2 8ED

Sponsor information

Organisation

Sponsor not yet defined (UK)

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary****Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	12/11/2013		Yes	No
Plain English results				No	Yes